PL3415517T3 - Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika - Google Patents

Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika

Info

Publication number
PL3415517T3
PL3415517T3 PL18185835T PL18185835T PL3415517T3 PL 3415517 T3 PL3415517 T3 PL 3415517T3 PL 18185835 T PL18185835 T PL 18185835T PL 18185835 T PL18185835 T PL 18185835T PL 3415517 T3 PL3415517 T3 PL 3415517T3
Authority
PL
Poland
Prior art keywords
methoxyurea
methoxypyridazin
tetrahydrothieno
difluorobenzyl
dimethylaminomethyl
Prior art date
Application number
PL18185835T
Other languages
English (en)
Inventor
Kazuhiro Miwa
Tsuyoshi Sasaki
Fumiya KOMURA
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49448235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3415517(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of PL3415517T3 publication Critical patent/PL3415517T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
PL18185835T 2012-09-28 2013-09-27 Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika PL3415517T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012217679 2012-09-28
PCT/JP2013/077013 WO2014051164A2 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
EP13779938.3A EP2900675B1 (en) 2012-09-28 2013-09-27 Production method of thienopyrimidine derivative
EP18185835.8A EP3415517B1 (en) 2012-09-28 2013-09-27 Crystalline form of 1-(4-1-(2,6-difluorobenzyl)-5-dimethylaminomethyl-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin-6yl)phenyl)-3-methoxyurea

Publications (1)

Publication Number Publication Date
PL3415517T3 true PL3415517T3 (pl) 2022-07-04

Family

ID=49448235

Family Applications (2)

Application Number Title Priority Date Filing Date
PL13779938T PL2900675T3 (pl) 2012-09-28 2013-09-27 Sposób wytwarzania pochodnej tienopirymidyny
PL18185835T PL3415517T3 (pl) 2012-09-28 2013-09-27 Postać krystaliczna 1-(4-1-(2,6-difluorobenzylo)-5-dimetyloaminometylo-3-(6-metoksypirydazyn-3-ylo)-2,4-diokso-1,2,3,4-tetrahydrotieno(2,3-d)-pirymidyn-6-ylo)fenylo)-3-metoksymocznika

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL13779938T PL2900675T3 (pl) 2012-09-28 2013-09-27 Sposób wytwarzania pochodnej tienopirymidyny

Country Status (21)

Country Link
US (10) US9758528B2 (pl)
EP (3) EP3415517B1 (pl)
JP (1) JP6250564B2 (pl)
CN (3) CN113372358B (pl)
AR (1) AR092707A1 (pl)
CA (1) CA2881132C (pl)
CY (2) CY1121641T1 (pl)
DK (2) DK2900675T3 (pl)
ES (2) ES2913753T3 (pl)
HR (2) HRP20190729T1 (pl)
HU (2) HUE044048T2 (pl)
LT (2) LT2900675T (pl)
PL (2) PL2900675T3 (pl)
PT (2) PT3415517T (pl)
RS (2) RS63199B1 (pl)
SI (2) SI2900675T1 (pl)
SM (2) SMT202200255T1 (pl)
TR (1) TR201906318T4 (pl)
TW (3) TWI602819B (pl)
UY (1) UY35058A (pl)
WO (1) WO2014051164A2 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
DK3539545T3 (da) * 2016-11-14 2021-09-27 Jiangsu Hengrui Medicine Co Krystallinsk form af gnrh-receptorantagonist og fremgangsmåde til fremstilling deraf
SG11201911598WA (en) 2017-06-05 2020-01-30 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
CN107188855A (zh) * 2017-07-14 2017-09-22 常州工程职业技术学院 一种3‑氨基‑6甲氧基哒嗪的制备方法
US12441738B2 (en) 2018-03-14 2025-10-14 Assia Chemical Industries Ltd. Solid state forms of Relugolix
WO2019178304A1 (en) 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
EP3666776A1 (en) 2018-12-11 2020-06-17 Sandoz AG Hydrate of a gonadotropin-releasing hormone receptor antagonist
WO2020230094A1 (en) * 2019-05-15 2020-11-19 Dr. Reddy’S Laboratories Limited Amorphous and crystalline forms of relugolix
CN110194776B (zh) * 2019-06-27 2021-05-28 四川伊诺达博医药科技有限公司 一种瑞卢戈利的合成方法
CN111943960B (zh) * 2019-07-29 2022-02-15 广东东阳光药业有限公司 取代的嘧啶二酮类化合物及其用途
WO2021026011A1 (en) * 2019-08-02 2021-02-11 Johnson Matthey Public Limited Company Solid-state forms of relugolix
CN112321602A (zh) * 2019-08-05 2021-02-05 苏州鹏旭医药科技有限公司 一种瑞卢戈利药物中间体的制备方法
CN112390812A (zh) * 2019-08-14 2021-02-23 苏州鹏旭医药科技有限公司 瑞卢戈利化合物的晶型和无定型固体及其制备方法
CN112771052B (zh) 2019-08-21 2023-04-07 深圳仁泰医药科技有限公司 促性腺素释放激素拮抗剂的晶型及其制备方法和用途
JP2022551316A (ja) * 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) * 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN112745304A (zh) * 2019-10-29 2021-05-04 上海度德医药科技有限公司 一种Relugolix的制备方法及中间体化合物
CN111423452B (zh) * 2020-03-26 2023-08-22 江西青峰药业有限公司 瑞卢戈利的中间体及其制备方法和应用
CN113444105A (zh) * 2020-03-27 2021-09-28 南京海润医药有限公司 一种Relugolix的制备方法
CN111333633B (zh) * 2020-04-01 2023-10-20 江西科睿药业有限公司 一种瑞卢戈利的中间体化合物及其制备方法和用途
CN111574534B (zh) * 2020-05-25 2021-06-04 东莞市东阳光新药研发有限公司 苯基取代的噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮类化合物及其用途
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina
US11655256B1 (en) 2020-11-06 2023-05-23 Macfarlan Smith Limited Processes for making a solid-state form of relugolix
EP4243829A1 (en) 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
CN112552312B (zh) * 2020-12-07 2022-08-05 杭州科巢生物科技有限公司 一种瑞卢戈利或其盐的合成方法
CN114685468A (zh) * 2020-12-25 2022-07-01 成都硕德药业有限公司 用于治疗子宫肌瘤的药物的中间体化合物及其制备方法
CN113620972A (zh) * 2021-02-02 2021-11-09 奥锐特药业(天津)有限公司 瑞卢戈利新晶型及其制备方法
CN114907370B (zh) 2021-02-10 2023-11-03 奥锐特药业(天津)有限公司 高纯度的噻吩并嘧啶化合物及其制备方法
CN115073491A (zh) * 2021-03-12 2022-09-20 上海医药工业研究院 一种瑞卢戈利中间体、其制备方法及其应用
WO2022214645A1 (en) 2021-04-09 2022-10-13 Farmhispania Group, S.L. Processes and intermediates for the preparation of relugolix
CA3217608A1 (en) * 2021-06-15 2022-12-22 Yuli Xie Idh mutant inhibitor and use thereof
CN115594688B (zh) * 2021-06-28 2023-11-17 成都倍特药业股份有限公司 瑞卢戈利中间体的制备方法
WO2023042214A1 (en) * 2021-09-15 2023-03-23 Cipla Limited Solid state forms of relugolix
WO2023066941A1 (en) * 2021-10-18 2023-04-27 Myovant Sciences Gmbh Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN114230576A (zh) * 2021-12-21 2022-03-25 伊诺药物研究(南京)有限公司 一种瑞卢戈利的制备方法
WO2023119333A1 (en) * 2021-12-25 2023-06-29 Dr. Reddy’S Laboratories Limited Process for preparation of relugolix and its intermediates
CN114409629B (zh) * 2022-02-22 2023-12-29 浙江科聚生物医药有限公司 一种高纯度Relugolix关键中间体的制备方法及应用
CN114790189B (zh) * 2022-02-24 2023-06-09 海化生命(厦门)科技有限公司 瑞卢戈利中间体的制备方法
CN114755320B (zh) * 2022-03-17 2024-10-01 南京方生和医药科技有限公司 一种3-氨基-6-甲氧基哒嗪有关物质的检测方法
IN202221021078A (pl) * 2022-04-08 2023-10-13
CN114621249B (zh) * 2022-04-27 2024-01-26 江苏慧聚药业股份有限公司 瑞卢戈利关键中间体的制备
CN119546611A (zh) * 2022-05-05 2025-02-28 台湾神隆股份有限公司 瑞卢戈利的制备工艺及其中间体
CN117069735A (zh) * 2022-05-10 2023-11-17 北京海美源医药科技有限公司 一种高效合成瑞卢戈利的方法和其应用
CN117285506A (zh) * 2022-07-14 2023-12-26 江西同和药业股份有限公司 一种瑞卢戈利中间体及其制备方法
CN115594689B (zh) * 2022-07-14 2024-03-19 江西同和药业股份有限公司 一种瑞卢戈利中间体、一种瑞卢戈利的合成方法
CN115417883B (zh) * 2022-09-16 2024-08-27 浙江科聚生物医药有限公司 一种瑞卢戈利的晶型及其制备方法
WO2024069492A1 (en) 2022-09-29 2024-04-04 Macfarlan Smith Limited Processes for the preparation and manufacture of relugolix
CN115650950A (zh) * 2022-11-03 2023-01-31 江西同和药业股份有限公司 一种瑞卢戈利中间体及其制备方法以及一种酰胺缩合方法
EP4634195A1 (en) 2022-12-15 2025-10-22 Medichem, S.A. Process for the preparation of relugolix
CN115650965B (zh) * 2022-12-26 2023-03-31 南京威凯尔生物医药科技有限公司 一种瑞卢戈利关键中间体的制备方法
WO2025037218A1 (en) * 2023-08-11 2025-02-20 Glenmark Life Sciences Limited Crystalline solvate of relugolix and a process for its preparation
CN117327091A (zh) * 2023-09-28 2024-01-02 浙江天宇药业股份有限公司 一种瑞卢戈利的合成方法
CN119859135B (zh) * 2023-10-19 2025-12-02 浙江工业大学 一种瑞卢戈利中间体及其制备方法
CN119859136A (zh) * 2023-10-19 2025-04-22 诚达药业股份有限公司 一种瑞卢戈利关键中间体化合物g及其制备方法
KR20250090216A (ko) 2023-12-12 2025-06-19 주식회사 와이에스생명과학 렐루골릭스의 제조방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5116436B1 (pl) * 1971-05-31 1976-05-24
EP0237289A3 (en) 1986-03-14 1988-07-27 Takeda Chemical Industries, Ltd. Pyrazolo [3,4-d] pyrimidine derivatives, their production and use
JP2859791B2 (ja) * 1992-01-31 1999-02-24 吉富製薬株式会社 ４−ブロモメチルビフェニル化合物の製造法
US5312958A (en) 1992-01-31 1994-05-17 Takeda Chemical Industries, Ltd. Process for producing 4-bromomethylbiphenyl compounds
FR2710637B1 (fr) 1993-09-28 1995-12-08 Roquette Freres Mannitol pulvérulent de friabilité modérée et son procédé de préparation.
JPH10298156A (ja) * 1997-04-28 1998-11-10 Nippon Nohyaku Co Ltd 置換ハロメチルフェニルカルバミド酸エステル類の製造方法
TWI225863B (en) * 1999-03-24 2005-01-01 Takeda Chemical Industries Ltd Thienopyrimidine compounds, their production and use
RU2233284C2 (ru) 1999-03-24 2004-07-27 Такеда Кемикал Индастриз, Лтд. Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона
KR20030005205A (ko) 2000-02-29 2003-01-17 다케다 야쿠힌 고교 가부시키가이샤 티에노피리미딘 유도체의 제조 방법
JP2001316391A (ja) * 2000-02-29 2001-11-13 Takeda Chem Ind Ltd チエノピリミジン誘導体の製造法
GB2361917A (en) * 2000-05-04 2001-11-07 Astrazeneca Ab Novel thieno[2,3-d]pyrimidinediones
JP2002068044A (ja) 2000-09-04 2002-03-08 Yamaha Motor Co Ltd 自動二輪車用ハンドルシート
JP2002088044A (ja) 2000-09-14 2002-03-27 Sumitomo Seika Chem Co Ltd ４’−ブロモメチル−２−シアノビフェニルの製造方法
CN1261437C (zh) 2001-09-04 2006-06-28 阿克佐诺贝尔公司 具有LH与FSH联合激动活性的甘氨酸－取代的噻吩并[2,3－d]嘧啶
WO2003057689A1 (en) 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them
US7569570B2 (en) * 2002-01-30 2009-08-04 Takeda Pharmaceutical Company Limited Thienopyrimidines, process for preparing the same and use thereof
BRPI0307786B8 (pt) 2002-02-26 2021-05-25 Astrazeneca Ab composição farmacêutica, método para preparar a mesma, métodos para inibir a taxa de precipitação do agente da solução no trato gi, e para reduzir variabilidade inter-pacientes no que se refere à biodisponibilidade e/ou concentrações plásmáticas do agente, e, uso de um celulose éter solúvel em água ou de um éster de um celulose éter solúvel em água
CN1333373C (zh) 2002-12-20 2007-08-22 皇家飞利浦电子股份有限公司 根据先前的图像增强来增强视频图像
ES2217956B1 (es) * 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
US7947691B2 (en) * 2004-07-21 2011-05-24 Athersys, Inc. Cyclic n-hydroxy imides as inhibitors of flap endonuclease and uses thereof
US20090131258A1 (en) 2004-10-25 2009-05-21 Nihon Nohyaku Co Herbicide compositions for upland farming and control method
KR20080041662A (ko) * 2005-07-22 2008-05-13 다케다 야쿠힌 고교 가부시키가이샤 조기 배란 예방제
TWI539959B (zh) 2008-02-11 2016-07-01 菲瑞茵國際中心股份有限公司 治療轉移階段攝護腺癌的方法
EP2329823A4 (en) 2008-09-03 2013-04-03 Takeda Pharmaceutical PROCESS FOR INCREASING THE ABSORPTION ABILITY OF A PREPARATION AND PREPARATION WITH INCREASED ABSORPTION ABILITY
EA024170B1 (ru) * 2011-02-23 2016-08-31 Люпин Лимитед ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ nAChR АЛЬФА7
JP2012217679A (ja) 2011-04-11 2012-11-12 Okumura Yu-Ki Co Ltd パチンコ遊技機
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
IL241595B2 (en) 2013-03-15 2025-10-01 Abbvie Inc Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids
US10821152B2 (en) 2014-08-26 2020-11-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗

Also Published As

Publication number Publication date
US20220135585A1 (en) 2022-05-05
US20170210753A1 (en) 2017-07-27
PT3415517T (pt) 2022-05-13
TWI602819B (zh) 2017-10-21
WO2014051164A2 (en) 2014-04-03
CY1125151T1 (el) 2024-12-13
US20190055261A1 (en) 2019-02-21
DK3415517T3 (da) 2022-05-30
US20220204525A1 (en) 2022-06-30
PL2900675T3 (pl) 2019-08-30
US20250051353A1 (en) 2025-02-13
TWI663171B (zh) 2019-06-21
TW201418262A (zh) 2014-05-16
TR201906318T4 (tr) 2019-05-21
SI3415517T1 (sl) 2022-06-30
SMT201900255T1 (it) 2019-07-11
DK2900675T3 (da) 2019-06-03
ES2724206T3 (es) 2019-09-09
SI2900675T1 (sl) 2019-06-28
US20150266891A1 (en) 2015-09-24
US10150778B2 (en) 2018-12-11
CA2881132C (en) 2020-11-24
CN104703992A (zh) 2015-06-10
US20200361953A1 (en) 2020-11-19
UY35058A (es) 2014-04-30
EP4119564A1 (en) 2023-01-18
EP3415517A1 (en) 2018-12-19
JP6250564B2 (ja) 2017-12-20
CN113372358B (zh) 2024-05-14
EP2900675A2 (en) 2015-08-05
AR092707A1 (es) 2015-04-29
US12325714B2 (en) 2025-06-10
LT2900675T (lt) 2019-05-27
US11053257B2 (en) 2021-07-06
US9758528B2 (en) 2017-09-12
US11795178B2 (en) 2023-10-24
US10464945B2 (en) 2019-11-05
CA2881132A1 (en) 2014-04-03
TW201906847A (zh) 2019-02-16
LT3415517T (lt) 2022-06-10
US10544160B2 (en) 2020-01-28
HRP20190729T1 (hr) 2019-06-14
HUE044048T2 (hu) 2019-09-30
CN113372358A (zh) 2021-09-10
EP2900675B1 (en) 2019-03-06
US11731983B2 (en) 2023-08-22
CY1121641T1 (el) 2020-07-31
US20230212184A1 (en) 2023-07-06
HUE059077T2 (hu) 2022-11-28
TW201808962A (zh) 2018-03-16
JP2015532262A (ja) 2015-11-09
EP3415517B1 (en) 2022-04-20
ES2913753T3 (es) 2022-06-06
HRP20220622T1 (hr) 2022-06-24
RS58703B1 (sr) 2019-06-28
US20250368660A1 (en) 2025-12-04
CN109053766B (zh) 2021-06-22
RS63199B1 (sr) 2022-06-30
WO2014051164A3 (en) 2014-05-22
TWI641611B (zh) 2018-11-21
CN104703992B (zh) 2019-03-05
US20180319816A1 (en) 2018-11-08
SMT202200255T1 (it) 2022-07-21
CN109053766A (zh) 2018-12-21
US12180224B2 (en) 2024-12-31
PT2900675T (pt) 2019-05-28

Similar Documents

Publication Publication Date Title
LT3415517T (lt) Kristalinė 1-(4-(1-(2,6-difluorbenzil)-5-dimetilaminometil-3-(6-metoksipiridazin-3-il)-2,4-diokso-1,2,3,4- tetrahidrotieno(2,3-d)pirimidin-6-il)fenil)-3-metoksikarbamido forma
ZA201407632B (en) Triazolone compounds as mpges-1 inhibitors
IL242285A0 (en) 4-Methoxy-n3-(pyrimidin-2-yl)benzene-3, 1-converted diamine compounds and their salts
HUE048012T2 (hu) Vízipipa-hõkezelõ tartozék
PL2836072T3 (pl) Kompozycja chwastobójcza zawierająca związek uracylowy jako składnik czynny
IL228345A0 (en) New pesticidal pyrazole compounds
ZA201408644B (en) Nitrogenated heterocyclic compound
ZA201208125B (en) Pyrazole compounds as jak inhibitors
GB201012105D0 (en) Novel pyrimidine compounds
ZA201309733B (en) Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
IL236326A0 (en) Analogues of modified bicyclic methoxypyrazole, preparations containing them and their uses
EP2936401A4 (en) MANAGEMENT OF INFORMATION TECHNOLOGY SERVICES
IL233800A0 (en) Pyrimidine compounds are fungicidal
IL233825A0 (en) Use of h1-indazole-3-carboxamide compounds as glycogen synthase kinase 3 inhibitors in the cell
GB201120644D0 (en) Herbicidal uses of compounds
IL226920A (en) Pyrazole compounds as antagonists of crth2
IL233799A0 (en) Pyrimidine compounds are fungicidal
SI2608789T2 (sl) Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina
ZA201303800B (en) Pyrazole compounds
ZA201302996B (en) Solid forms of 3-(4-(aminomethyl)-1-(5-methyl-7h-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamido)phenyl dimethylcarbamate
HK1188394A (en) Formulations of phenyl uracil compounds
AP2014008073A0 (en) Nitrogenated heterocyclic compound
IL218571A0 (en) Resolution of 1 - (4 - methoxybenzyl) octahydro - isoquinoline